R&D investment benchmarked at approximately 10% of revenue
First written in FY2017-Q1. 28 of 30 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total research and development expenses for the group were ¥7,816 million.」
Research and development expenses were ¥7,816 million, and the company disclosed progress on GGS's approximately ¥20 billion research and development investment plan for the fiscal years ending March 2025 through March 2027. - FY2026-H1RestatedAnnual report
「Total research and development expenses for the six months ended the interim period were ¥3,290 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥3,290 million for the six months ended the interim period. - FY2025RestatedAnnual report
「Total research and development expenses for the group were ¥6,386 million.」
The company continued its research and development activities and disclosed total research and development expenses of ¥6,386 million for the fiscal year. - FY2025-H1RestatedAnnual report
「Total research and development expenses for the six months ended the interim period were ¥2,628 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥2,628 million for the six months ended the interim period. - FY2024-Q3RestatedAnnual report
「Total research and development expenses for the nine months ended the third quarter were ¥3,517 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company disclosed research and development expenses of ¥3,517 million for the nine months ended the third quarter and stated that there were no material changes in its research and development activities, while continuing research and development investment focused on the agrochemicals business. - FY2024-Q2RestatedAnnual report
「Total research and development expenses for the six months ended the second quarter were ¥2,117 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company disclosed research and development expenses of ¥2,117 million for the six months ended the second quarter and stated that there were no material changes in its research and development activities, while continuing research and development investment focused on the agrochemicals business. - FY2024-Q1RestatedAnnual report
「Total research and development expenses for the three months ended the first quarter were ¥975 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company reported research and development expenses of ¥975 million and explained that there were no material changes in the status of its research and development activities. - FY2023RestatedAnnual report
「The company will continue to make strategic investments in research and development for new agents currently under development in order to steadily bring them to commercialisation.」
The company continues research and development investment aimed at commercialising new agents. Total research and development expenses were ¥5,211 million. - FY2023-Q1RestatedAnnual report
「Total research and development expenses for the three months ended the first quarter were ¥962 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company stated that there were no material changes in its research and development activities and disclosed total research and development expenses of ¥962 million for the three months ended the first quarter. - FY2022RestatedAnnual report
「The company will continue to make strategic investments in research and development for new agents currently under development, equivalent to approximately 10% of sales, to steadily bring them to commercialisation.」
The company has reaffirmed its policy of continuing research and development investment equivalent to approximately 10% of sales to commercialise new agents. Total research and development expenses were ¥4,681 million. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the nine months ended the third quarter were ¥3,143 million for the group as a whole, mainly related to the agrochemicals business.」
The company continued research and development investment, mainly in the agrochemicals business, and reported total research and development expenses of ¥3,143 million for the nine months ended the third quarter. - FY2022-Q2RestatedAnnual report
「Total research and development expenses for the six months ended the second quarter were ¥1,911 million for the group as a whole, mainly related to the agrochemicals business.」
The company reported total research and development expenses of ¥1,911 million for the six months ended the second quarter and reaffirmed its commitment to continued research and development investment. - FY2022-Q1RestatedAnnual report
「Total research and development expenses for the three months ended the first quarter were ¥875 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥875 million for the first quarter. - FY2021RestatedAnnual report
「The company will continue to make strategic investments in research and development for new agents currently under development, equivalent to approximately 10% of sales, to steadily bring them to commercialisation.」
The company has reaffirmed its policy of continuing research and development investment equivalent to approximately 10% of sales under its new medium-term management plan, with the aim of commercialising new agents. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the nine months ended the third quarter were ¥3,053 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company disclosed research and development expenses of ¥3,053 million for the nine months ended the third quarter and stated that there were no material changes in its research and development activities. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the six months ended the second quarter were ¥1,846 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company reported research and development expenses of ¥1,846 million and explained that there were no material changes in the status of its research and development activities. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the three months ended the first quarter were ¥851 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
The company stated that there were no material changes in its research and development activities and reported research and development expenses of ¥851 million for the first quarter. - FY2020-Q1RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its policy of using approximately 10% of sales as a benchmark for research and development investment. Research and development expenses for the nine months ended the third quarter were ¥3,030 million. - FY2019-Q4RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its research and development investment policy of using approximately 10% of annual sales as a benchmark. - FY2019-Q3RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its research and development investment policy of using approximately 10% of annual sales as a benchmark. Research and development expenses for the three months ended the first quarter were ¥1,218 million. - FY2018RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its annual research and development investment policy, using approximately 10% of sales as a benchmark. Total research and development expenses were ¥4,690 million. - FY2019-Q1RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its annual research and development investment policy, using approximately 10% of sales as a benchmark. Research and development expenses for the nine months ended the third quarter were ¥3,387 million. - FY2018-Q4RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its annual research and development investment policy, using approximately 10% of sales as a benchmark. Research and development expenses for the six months ended the second quarter were ¥2,058 million. - FY2018-Q3RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its policy of using approximately 10% of sales each year as a benchmark for research and development investment. Research and development expenses for the three months ended the first quarter were ¥982 million. - FY2017RestatedAnnual report
「The company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its policy of using approximately 10% of sales as a benchmark for research and development investment. Total research and development expenses for the fiscal year were ¥5,014 million. - FY2018-Q1RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its policy of using approximately 10% of sales each year as a benchmark for research and development investment. Research and development expenses for the nine months ended the third quarter were ¥3,329 million. - FY2017-Q4RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its policy of using approximately 10% of sales each year as a benchmark for research and development investment. Research and development expenses for the six months ended the second quarter were ¥2,331 million. - FY2017-Q3RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company has reaffirmed its policy of using approximately 10% of sales as a benchmark for research and development investment. Research and development expenses in the first quarter were ¥1,232 million. - FY2016RestatedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year.」
The company has reiterated its policy of using approximately 10% of sales as a benchmark for research and development investment. - FY2017-Q1First statedAnnual report
「Under these circumstances, the company invests approximately 10% of sales in research and development each year, with the aim of achieving, maintaining and improving a high probability of successful drug discovery.」
The company uses approximately 10% of annual sales as a benchmark for research and development investment.